Farms.com Home   News

Previous Infection of Sows with a "Mild" Strain of Porcine Epidemic Diarrhea Virus Confers Protection against Infection with a "Severe" Strain

Porcine epidemic diarrhea virus (PEDv) infected approximately 50% of the US swine breeding herds from July 2013 to July 2014 as estimated by the Swine Health Monitoring Project. In the absence of effective vaccines or standard control protocols, there is an urgent need for evidence of cross-protective immune countermeasures. Here, we evaluated the response of 3-day-old piglets born to sows exposed seven months earlier to a mild strain of PEDv to challenge with a virulent PEDv isolate. Piglet survival to one week of age was 100% compared to 67% in piglets born to sows not previously exposed, and morbidity was 43% compared to 100%, respectively. At necropsy at 7 days of age, the PEDv Ct value was 23.6 (range 16.6-30.6) in intestinal contents, compared to 17.2 (range 15.9-18.5) (p<0.06) in litters from sows with no previous exposure to PEDv. The findings indicated that durable lactogenic immunity was present in sows previously exposed to a mild strain of PEDv and this immunity induced cross-protection to representative virulent PEDv. Thus, a naturally attenuated form of PEDv provided significant passive immune protection for seven months against piglet challenge with virulent PEDv.

Source: AASV


Trending Video

New discovery may lead to better vaccines for pork producers

Video: New discovery may lead to better vaccines for pork producers



Porcine reproductive and respiratory syndrome virus (PRRSV) causes severe disease in pigs, leading to significant economic losses for pork producers across the globe. It’s estimated that PRRS costs the Canadian pork industry $130M annually. Using the CMCF beamline, researchers from the University of Manitoba and the Leiden University Medical Centre (Netherlands) were able to see the structure of the PRRSV protease, a type of protein the pathogen uses to suppress a host’s immune system. The vital information they uncovered can be used to develop new vaccines against PRRSV and also helps inform development of vaccines against emerging human viruses.